Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single and repeated dose study of STN1013400 ophthalmic solution in healthy adult males
jRCT2031210208Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of STN1013400 in myopia (3 arms), sponsored by Santen Pharmaceutical. Primary endpoints: Safety (adverse events and adverse drug reactions) and Plasma pharmacokinetics of STN1013400. Started Jul 2021; status: completed.
02
Drugs
STN1013400
03
Conditions
myopia
Beyond the preview
Go deeper on jRCT2031210208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210208.